Format

Send to

Choose Destination
Mitochondrion. 2006 Jun;6(3):126-35. Epub 2006 May 3.

Therapeutic potential of dichloroacetate for pyruvate dehydrogenase complex deficiency.

Author information

1
Division of Endocrinology and Metabolism, Department of Medicine, University of Florida College of Medicine, P.O. Box 10226, Gainesville, FL 32610, USA. berenkm@medicine.efl.edu

Abstract

We reviewed the use of oral dichloroacetate (DCA) in the treatment of children with congenital lactic acidosis caused by mutations in the pyruvate dehydrogenase complex (PDC). The case histories of 46 subjects were analyzed with regard to diagnosis, clinical presentation and response to DCA. DCA decreased blood and cerebrospinal fluid lactate concentrations, and was generally well tolerated. DCA may be particularly effective in children with PDC deficiency by stimulating residual enzyme activity and, consequently, cellular energy metabolism. A controlled trial is needed to determine the definitive role of DCA in the management of this devastating disease.

PMID:
16725381
DOI:
10.1016/j.mito.2006.04.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center